AR105176A2 - Procedimiento para preparar una sal de tipo camsilato - Google Patents

Procedimiento para preparar una sal de tipo camsilato

Info

Publication number
AR105176A2
AR105176A2 ARP160101953A ARP160101953A AR105176A2 AR 105176 A2 AR105176 A2 AR 105176A2 AR P160101953 A ARP160101953 A AR P160101953A AR P160101953 A ARP160101953 A AR P160101953A AR 105176 A2 AR105176 A2 AR 105176A2
Authority
AR
Argentina
Prior art keywords
indene
cyclohexane
methoxy
methyl
imidazole
Prior art date
Application number
ARP160101953A
Other languages
English (en)
Inventor
Robert Stewart Craig
Hans Bohlin Martin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR105176A2 publication Critical patent/AR105176A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un procedimiento de preparación de una sal de tipo camsilato de (1r,1R,4R)-4-metoxi-5-metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4-amina que comprende reaccionar (1r,1R,4R)-4-metoxi-5-metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4-amina con ácido (1S)-(+)-10-camforsulfónico. Reivindicación 1: Un procedimiento para preparar una sal de tipo camsilato de (1r,1R,4R)-4-metoxi-5-metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4-amina de fórmula (1), caracterizado porque el procedimiento comprende hacer reaccionar (1r,1R,4R)-4-metoxi-5-metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4-amina de fórmula (2) con (1S)-(+)-10-camforsulfónico de fórmula (3). Reivindicación 2: El procedimiento según la reivindicación 1, caracterizado porque el compuesto (1r,1R,4R)-4-metoxi-5-metil-6-[5-(prop-1-in-1-il)piridin-3-il]-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4-amina se prepara según un procedimiento que comprende hacer reaccionar la sal del ácido (+)-10-camforsulfónico de (1r,4r)-6-bromo-4-metoxi-5-metil-3H-dispiro[ciclohexan-1,2-indeno-1,2-imidazol]-4-amina de fórmula (4) con ácido 5-(prop-1-inil)piridin-3-ilborónico de fórmula (5) en presencia de un catalizador de metal de transición y una base. Reivindicación 5: El procedimiento según cualquiera de las reivindicaciones 1 - 4, caracterizado porque dicha sal del ácido (+)-10-camforsulfónico de (1r,4r)-6-bromo-4-metoxi-5-metil-3H-dispiro[ciclohexan-1,2-indeno-1,2-imidazol]-4-amina se prepara según un procedimiento que comprende hacer reaccionar (1r,4r)-6-bromo-4-metoxi-5-metil-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4(3H)-tiona de fórmula (6) con amoniaco en presencia de acetato de zinc dihidratado, seguido de la adición de ácido (1S)-(+)-10-camforsulfónico. Reivindicación 6: El procedimiento según la reivindicación 5, caracterizado porque dicho compuesto (1r,4r)-6-bromo-4-metoxi-5-metil-3H-diespiro[ciclohexano-1,2-indeno-12-imidazol]-4(3H)-tiona se prepara según un procedimiento que comprende hacer reaccionar clorhidrato de (1r,4r)-6-bromo-4-metoxiespiro[ciclohexano-1,2-indeno]-1(3H)-imina de fórmula (7) con 2-oxopropanotioamida.
ARP160101953A 2012-06-21 2016-06-28 Procedimiento para preparar una sal de tipo camsilato AR105176A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
AR105176A2 true AR105176A2 (es) 2017-09-13

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130102162 AR091495A1 (es) 2012-06-21 2013-06-19 Sal de tipo camsilato
ARP160101953A AR105176A2 (es) 2012-06-21 2016-06-28 Procedimiento para preparar una sal de tipo camsilato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130102162 AR091495A1 (es) 2012-06-21 2013-06-19 Sal de tipo camsilato

Country Status (42)

Country Link
US (1) US10548882B2 (es)
EP (2) EP3064494A1 (es)
JP (2) JP2015520221A (es)
KR (1) KR102123708B1 (es)
CN (2) CN104411697B (es)
AP (2) AP2017009693A0 (es)
AR (2) AR091495A1 (es)
AU (2) AU2013279109B2 (es)
BR (2) BR122016014302B1 (es)
CA (1) CA2875589C (es)
CL (1) CL2014003374A1 (es)
CO (1) CO7151486A2 (es)
CR (2) CR20140571A (es)
CY (1) CY1119505T1 (es)
DK (1) DK2864316T3 (es)
DO (1) DOP2014000268A (es)
EC (1) ECSP14032215A (es)
ES (1) ES2618939T3 (es)
HK (1) HK1206349A1 (es)
HR (1) HRP20170359T1 (es)
HU (1) HUE033376T2 (es)
IL (1) IL236131A0 (es)
IN (1) IN2014DN10088A (es)
LT (1) LT2864316T (es)
MA (2) MA39259B1 (es)
ME (1) ME02633B (es)
MX (1) MX354214B (es)
NI (1) NI201400146A (es)
NZ (2) NZ727045A (es)
PE (1) PE20150670A1 (es)
PH (2) PH12014502803A1 (es)
PL (1) PL2864316T3 (es)
PT (1) PT2864316T (es)
RS (1) RS55815B1 (es)
RU (1) RU2638175C2 (es)
SG (1) SG11201407934UA (es)
SI (1) SI2864316T1 (es)
TN (1) TN2014000491A1 (es)
TW (2) TWI588140B (es)
UA (1) UA114196C2 (es)
WO (1) WO2013190302A1 (es)
ZA (1) ZA201500408B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
AR102202A1 (es) 2014-10-07 2017-02-08 Astrazeneca Ab Compuestos de oxazol y su uso como inhibidores de bace de oxazol
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
KR20180119670A (ko) 2016-03-15 2018-11-02 아스트라제네카 아베 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합
BR112021017960A2 (pt) * 2019-03-14 2021-11-23 Astrazeneca Ab Lanabecestate para perda de peso

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (fr) 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1729771B1 (en) 2004-03-22 2009-10-14 Eli Lilly & Company Pyridyl derivatives and their use as mglu5 receptor antagonists
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
TW200734311A (en) * 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
US20090176850A1 (en) 2005-11-21 2009-07-09 Astrazeneca Ab Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
EP1966163A1 (en) 2005-12-21 2008-09-10 Boehringer Ingelheim International GmbH Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
AR061264A1 (es) 2006-06-12 2008-08-13 Schering Corp Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih.
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
WO2008092877A2 (en) 2007-02-01 2008-08-07 Glaxo Group Limited 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
EP2324032B1 (en) 2008-08-19 2014-10-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
ES2459195T3 (es) 2008-09-11 2014-05-08 Amgen Inc. Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
KR20120001756A (ko) 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
TW201103893A (en) 2009-07-02 2011-02-01 Astrazeneca Ab New compounds
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011123674A1 (en) 2010-03-31 2011-10-06 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US20120083501A1 (en) 2010-09-24 2012-04-05 Hunt Kevin W Compounds for treating neurodegenerative diseases
TW201307357A (zh) 2010-11-22 2013-02-16 Array Biopharma Inc 治療神經退化性疾病之化合物
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
KR20150023388A (ko) 2015-03-05
CN106279102A (zh) 2017-01-04
MA37666A1 (fr) 2016-04-29
ES2618939T3 (es) 2017-06-22
PL2864316T3 (pl) 2017-09-29
JP6509393B2 (ja) 2019-05-08
SG11201407934UA (en) 2015-01-29
TWI588140B (zh) 2017-06-21
MA37666B1 (fr) 2016-12-30
ME02633B (me) 2017-06-20
PE20150670A1 (es) 2015-06-03
PH12014502803B1 (en) 2015-02-23
CN104411697B (zh) 2016-08-10
AP2017009693A0 (en) 2017-01-31
AU2017254965A1 (en) 2017-11-23
PH12016500498A1 (en) 2017-04-10
MA39259B1 (fr) 2018-09-28
BR112014031531B1 (pt) 2022-08-02
US10548882B2 (en) 2020-02-04
PH12014502803A1 (en) 2015-02-23
DOP2014000268A (es) 2015-04-15
BR122016014302B1 (pt) 2022-08-23
AR091495A1 (es) 2015-02-11
MX354214B (es) 2018-02-19
CL2014003374A1 (es) 2015-02-27
AU2013279109B2 (en) 2017-08-31
WO2013190302A1 (en) 2013-12-27
TW201730177A (zh) 2017-09-01
MX2014014709A (es) 2015-03-04
IN2014DN10088A (es) 2015-08-21
EP2864316A1 (en) 2015-04-29
NZ702742A (en) 2016-12-23
DK2864316T3 (en) 2017-03-20
HK1206349A1 (zh) 2016-01-08
ZA201500408B (en) 2016-10-26
CY1119505T1 (el) 2018-03-07
TW201406745A (zh) 2014-02-16
HUE033376T2 (en) 2017-11-28
MA39259A1 (fr) 2017-12-29
CR20140571A (es) 2015-02-04
EP3064494A1 (en) 2016-09-07
CN104411697A (zh) 2015-03-11
AU2017254965B2 (en) 2019-05-09
RU2014148305A (ru) 2016-08-10
HRP20170359T1 (hr) 2017-05-05
CO7151486A2 (es) 2014-12-29
NI201400146A (es) 2016-09-21
IL236131A0 (en) 2015-02-01
CA2875589C (en) 2020-08-25
CR20160202A (es) 2016-07-26
RS55815B1 (sr) 2017-08-31
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
JP2018104448A (ja) 2018-07-05
RU2638175C2 (ru) 2017-12-12
TN2014000491A1 (en) 2016-03-30
BR122016014302A2 (pt) 2019-08-27
TWI639591B (zh) 2018-11-01
US20140031379A1 (en) 2014-01-30
KR102123708B1 (ko) 2020-06-16
LT2864316T (lt) 2017-03-27
JP2015520221A (ja) 2015-07-16
NZ727045A (en) 2018-06-29
AP2014008137A0 (en) 2014-12-31
ECSP14032215A (es) 2015-12-31
SI2864316T1 (sl) 2017-04-26
UA114196C2 (uk) 2017-05-10
PT2864316T (pt) 2017-02-24
BR112014031531A2 (pt) 2017-06-27
EP2864316B1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
AR105176A2 (es) Procedimiento para preparar una sal de tipo camsilato
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
PH12015502839A1 (en) Antiviral compounds
MX2021014128A (es) Polimorfos de selinexor.
CR20150370A (es) Compuestos antivirales
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
PE20151090A1 (es) Lactamas fusionadas de arilo y heteroarilo
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
IN2014DN08867A (es)
MY178407A (en) Process for the production of solid cooling agents
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
GEP201706749B (en) Vortioxetine manufacturing process
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
MX2015011280A (es) Moduladores de ship1 y metodos relacionados con los mismos.
MX348979B (es) Agente de control de enfermedades de las plantas.
MX2016015454A (es) Proceso para preparar acido 3-metil-2-nitrobenzoico por oxidacion del aire.
MY174153A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IN2013DE02503A (es)
AR092627A1 (es) Derivados glucopiranosidos de urea
MX368855B (es) Compuestos de flavonoides novedosos y sus usos.
MX353410B (es) Tinturas ácidas, proceso para su producción y su uso.
DOP2017000158A (es) Sal de tipo camsilato
MX2016005220A (es) Tinturas acidas, proceso para su produccion y su uso.
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure